Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status Prescription
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 65977-0049; 70518-1621; 17381-749; 68071-2113; 0006-3080; 0006-0477; 0006-0473; 0006-0227; 50090-1085; 0006-3603
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.0010.002956%Not Available
Lymph node pain01.09.01.0070.007554%
Lymphadenopathy01.09.01.0020.007554%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.004926%Not Available
Malabsorption14.02.01.004; 07.17.01.0010.007554%
Malaise08.01.01.003--
Memory impairment19.20.01.003; 17.03.02.0030.011331%
Meningitis cryptococcal17.06.04.001; 11.03.04.0020.001971%Not Available
Meningomyelocele03.10.02.006; 17.19.01.0060.011331%Not Available
Microcephaly15.11.02.002; 03.11.02.0020.022661%Not Available
Mucosal inflammation08.01.06.0020.007554%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.0010.030215%
Myocardial infarction24.04.04.009; 02.02.02.0070.009853%
Myopathy15.05.05.0010.011331%Not Available
Myositis15.05.01.0010.007554%
Nasopharyngitis11.01.13.002; 22.07.03.0020.018884%Not Available
Nausea07.01.07.0010.098199%
Neoplasm malignant16.16.01.0010.002956%Not Available
Nephrolithiasis20.04.01.0020.011331%
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.015108%Not Available
Osteoporosis14.04.04.002; 15.02.03.0020.026438%
Oxygen saturation decreased13.02.01.0040.011331%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain in jaw15.02.01.0030.007554%Not Available
Palpitations02.01.02.0030.011331%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages